FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, particularly to genetic engineering and it can be used in the biomedical industry to produce active medications of interleukin-29 (IL-29). Mutant forms of IL-29 (SEQ ID NO: 27, 29, 40, 41, 149 and 159) were offered with substitution of the cysteine residue in the position in accordance with position 171 of the aminoacid sequence of a mature protein of a wild type that are characterised by a correct formation of intramolecular disulfide bonds and accordingly they provide production of polypeptides with an antiviral activity as homogeneous medications at expression in the heterologous system.
EFFECT: vector structures and the host cells transformed by these structures for the expression of new versions of IL-29 are described.
15 cl, 37 tbl, 45 ex
Title | Year | Author | Number |
---|---|---|---|
HOMOGENOUS PREPARATIONS OF IL-28 AND IL-29 | 2004 |
|
RU2518324C2 |
INTERFERON-LIKE PROTEIN ZCYTO21 | 2001 |
|
RU2292394C2 |
USING TYPE III PEGYLATED INTERFERONS FOR TREATING HEPATITIS C | 2009 |
|
RU2496514C2 |
COMPOSITION FOR IMMUNIZATION (VARIANTS), METHOD FOR ITS PREPARING AND USING FOR TREATMENT OF ALLERGIC EOSINOPHILIC DISEASES | 2002 |
|
RU2319503C2 |
CONJUGATES OF PEPTIDE Melan-A, VIRUS-LIKE PARTICLE ANALOGUE | 2004 |
|
RU2351362C2 |
NOVEL SOLUBLE POLYPEPTIDES CD83, COMPOSITIONS AND METHODS OF THEIR APPLICATION | 2009 |
|
RU2535340C2 |
MUTANT POLYPEPTIDES SUAA AND POLYPEPTIDE DERIVATIVES SUITABLE FOR DELIVERY OF IMMUNOGENIC MOLECULES IN CELL | 2010 |
|
RU2585216C2 |
RECOMBINANT VACCINE OF FELINE LEUKEMIA VIRUS CONTAINING OPTIMISED GENE OF FELINE LEUKEMIA VIRAL ENVELOPE | 2012 |
|
RU2591817C2 |
IMMUNOSUPPRESSIVE POLYPEPTIDES AND NUCLEIC ACIDS | 2008 |
|
RU2506275C2 |
ISOLATED SOLUBLE IL-20 RECEPTOR (VARIANTS) | 2000 |
|
RU2279441C2 |
Authors
Dates
2009-11-10—Published
2004-08-09—Filed